anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to an anticancer prodrug represented by chemical formula 1. The anticancer prodrug of the present invention is able to rapidly alkylate antioxidant GSH by releasing two quinone methides by esterase and thus, to inhibit an antioxidant system and significantly increase oxidative stress. The anticancer prodrug of the present invention induces the death of cancer cells through an increase in oxidative stress due to GSH deficiency. Additionally, the anticancer prodrug of the present invention induces the loss of a mitochondrial membrane, inhibits the expression of apoptosis-related protein Bcl-2, and induces cleavage of caspase-3 and PARP-1. The anticancer prodrug of the present invention significantly inhibits tumor growth and does not cause chronic damage even when being administered for a long period of time and thus, can be useful for the prevention or treatment of cancer. In the chemical formula 1, R is an alkyl group, a phenyl group, a naphthyl group, or an anthracenyl group selected from a group consisting of methyl, ethyl, propyl, butyl, and t-butyl, respectively.
The invention relates to the discovery and purification of novel estrogen response element binding proteins. Estrogen response element binding proteins are distinct from the estrogen receptor and other intracellular receptors, e.g. estrogen receptor. Estrogen response element binding proteins can interfere with the biological activity of the estrogen receptor and other related intracellular receptor proteins. One aspect of the invention is to provide purified estrogen response element binding proteins. Another aspect of the invention is to provide antibodies capable of binding to the estrogen response element binding proteins of the invention. Another aspect of the invention is to provide assays for the detection or screening of therapeutic compounds that interfere with the interaction between estrogen response element binding protein and estrogen response elements.
BACKGROUND: Although abnormal heart rate variability (HRV) is frequently observed in patients with spontaneous intracerebral hemorrhage (ICH), its time course and presentation of different indices remain unclear, and few studies have focused on its association with clinical outcomes.
METHODS: We prospectively recruited consecutive patients with spontaneous ICH between June 2014 and June 2021. HRV was evaluated twice during hospitalization (within 7 days and 10-14 days after stroke). Time and frequency domain indices were calculated. A modified Rankin Scale score ≥ 3 at 3 months was defined as a poor outcome.
RESULTS: Finally, 122 patients with ICH and 122 age- and sex-matched volunteers were included. Compared with controls, time domain and absolute frequency domain HRV parameters (total power, low frequency [LF], and high frequency [HF]) in the ICH group were significantly decreased within 7 days and 10-14 days. For relative values, normalized LF (LF%) and LF/HF were significantly higher, whereas normalized HF (HF%) was significantly lower, in the patient group than in the control group. Furthermore, LF% and HF% measured at 10-14 days were independently associated with 3-month outcomes.
CONCLUSIONS: HRV values were impaired significantly within 14 days after ICH. Furthermore, HRV indices measured 10-14 days after ICH were independently associated with 3-month outcomes.
BACKGROUND: Dexmedetomidine and propofol are common sedatives in intensive care units and for interventional procedures. Both may compromise sinus node function and atrioventricular conduction. The objective of this prospective, randomized study is to compare the effect of dexmedetomidine with propofol on sinus node function and atrioventricular conduction.
METHODS: In a tertiary care center in Switzerland we included from September 2019 to October 2020 160 patients (65 ± 11 years old; 32% female) undergoing first ablation for atrial fibrillation by cryoballoon ablation or by radiofrequency ablation. Patients were randomly assigned to deep sedation with dexmedetomidine (DEX group) versus propofol (PRO group). A standard electrophysiological study was performed after pulmonary vein isolation with the patients still deeply sedated and hemodynamically stable.
RESULTS: Eighty patients each were randomized to the DEX and PRO group. DEX group patients had higher baseline sinus cycle length (1022 vs. 1138 ms; p = 0.003) and longer sinus node recovery time (SNRT400; 1597 vs. 1412 ms; p = 0.042). However, both corrected SNRT and normalized SNRT did not differ. DEX group patients had longer PR interval (207 vs. 186 ms; p = 0.002) and AH interval (111 vs. 95 ms, p = 0.008), longer Wenckebach cycle length of the atrioventricular node (512 vs. 456 ms; p = 0.005), and longer atrioventricular node effective refractory period (390 vs. 344 ms; p = 0.009). QRS width and HV interval were not different. An arrhythmia, mainly atrial fibrillation, was induced in 33 patients during the electrophysiological study, without differences among groups (20% vs. 15%, p = 0.533).
CONCLUSIONS: Dexmedetomidine has a more pronounced slowing effect on sinus rate and suprahissian AV conduction than propofol, but not on infrahissian AV conduction and ventricular repolarization. These differences need to be taken into account when using these sedatives.
TRIAL REGISTRATION: ClinicalTrials.gov number NCT03844841, 19/02/2019.
BACKGROUND: During systemic therapy, the management of portal hypertension (PH)-related complications is vital. This study aimed to clarify factors associated with the incidence and exacerbation of PH-related complications, including the usefulness of contrast-enhanced computed tomography (CECT) in the management of PH-related complications during systemic therapy.
METHODS: A total of 669 patients who received systemic therapy as first-line treatment (443 patients for sorafenib, 131 for lenvatinib, and 90 for atezolizumab/bevacizumab [ATZ/BEV]) were enrolled in this retrospective study. Additionally, the lower esophageal intramural vessel diameters (EIV) on CECT and endoscopic findings in 358 patients were compared.
RESULTS: The cutoff values of the EIV diameter on CECT were 3.1 mm for small, 5.1 mm for medium, and 7.6 mm for large varices, demonstrating high concordance with the endoscopic findings. esophageal varices (EV) bleeding predictors include EIV ≥ 3.1 mm and portal vein tumor thrombosis (PVTT). In patients without EV before systemic therapy, factors associated with EV exacerbation after 3 months were EIV ≥ 1.9 mm and ATZ/BEV use. Predictors of hepatic encephalopathy (HE) include the ammonia level or portosystemic shunt diameter ≥ 6.8 mm. The incidence of HE within 2 weeks was significantly higher (18%) in patients with an ammonia level ≥ 73 μmol/L and a portosystemic shunt ≥ 6.8 mm. The exacerbating factors for ascites after 3 months were PVTT and low albumin levels.
CONCLUSIONS: Careful management is warranted for patients with risk factors for exacerbation of PH-related complications; moreover, the effective use of CECT is clinically important.
1,249,478. Treating hair. L'OREAL. 25 Oct., 1968 [26 Oct., 1967], No. 2911/71. Divided out of 1,249,477. Heading D1P. Human hair is treated with a "self neutralising" composition for permanent waving, which comprises at least one thiol or disulphide and at least one polycondensate compound containing at least one group of the formula: in which X represents O or S, each of R 1  and R 2 , which may be the same or different, represents an alkyl of 1-6 C atoms or R 1  and R 2  together with the N atom to which they are attached form a heterocyclic radical, and each of the R 3  radicals, which may be the same or different, represents an H atom or an alkyl radical, or two R 3  groups together form a divalent radical; or a salt thereof containing at least one group of the formula: in which X, R 1 , R 2  and R 3  are as above. R 5  is an alkyl group or other salt forming group e.g. when R 1  and R 2  together form a heterocyclic radical, R, represents, in effect, a double bond forming part of the heterocyclic ring and A represents a halide ion. The groups are attached to a radical containing a disulphide or thiol group respectively. Examples of the polycondensable compound are N-carbamyl-N'-morpholinomethyl carbamyl cysteamine, N-N'-di (morpholinomethylcarbamyl) cysteamine, N-morpholinemethylcarbamyl) cysteamine, N-morpholinemethylcarbamyl cysteamine and N-N' dimethyl, -N-#-ureidoethyl-N' N'-dimethyl-N'-# - (morpholinomethylureylen) ethyl cysteamine dichloride. The cosmetic compositions are in the form of aqueous, or aqueous-alcoholic solutions, creams, gels or aerosols containing 0.5-12% by weight of at least one of the polycondensable compounds. The composition may also comprise a urea or urein, which are optionally substituted by a disulphide, thiol, carboxylic acid, tertiary or quaternary ammonium group or by a fatty chain e.g. an alkyl or alkenyl radical of 12-30 C atoms. Also the composition may contain surface active agents, penetrating agents and perfumes. A two-component pack is provided comprising as component (A), at least one of the polycondensable compounds containing a disulphide or thiol group and as component (B) a thiol or disulphide respectively. An acid catalyst, which is either an inorganic or organic acid or an acid salt e.g. acetic, lactic or phosphoric acid may be present in component (B) to catalyse the polycondensation in the keratinic fibre on heating.
U.S. geriatric clinical studies of sertraline hydrochloride in major depressive disorder included 663 sertraline hydrochloride-treated subjects ≥ 65 years of age, of those, 180 were ≥ 75 years of age. No overall differences in the pattern of adverse reactions were observed in the geriatric clinical trial subjects relative to those reported in younger subjects (see ADVERSE REACTIONS), and other reported experience has not identified differences in safety patterns between the elderly and younger subjects. As with all medications, greater sensitivity of some older individuals cannot be ruled out. There were 947 subjects in placebo-controlled geriatric clinical studies of sertraline hydrochloride in major depressive disorder. No overall differences in the pattern of efficacy were observed in the geriatric clinical trial subjects relative to those reported in younger subjects. 

Other Adverse Events in Geriatric Patients. In 354 geriatric subjects treated with sertraline hydrochloride in placebo-controlled trials, the overall profile of adverse events was generally similar to that shown in Tables 2 and 3. Urinary tract infection was the only adverse event not appearing in Tables 2 and 3 and reported at an incidence of at least 2% and at a rate greater than placebo in placebo-controlled trials.

SSRIS and SNRIs, including sertraline hydrochloride, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event (see PRECAUTIONS, Hyponatremia).
The invention relates to hair-treatment compositions which are free of oxidising agents. The compositions contain     0.01-2.00% by weight of 4-isopropyldibenzoylmethane   0.01-2.00% by weight of 3-(4-methylbenzylidene)camphor   0.01-1.00% by weight of 2-hexyl-3-phenyl-2-propenal 0.01-1.00% by weight of  alpha -methyl- beta -(p-tert-butylphenyl)propionaldehyde.   The products may remain in the hair or be rinsed out again after acting for several minutes. The compositions display excellent protection against sunlight and UV radiation and an outstanding effect against oxidation by atmospheric oxygen. The combinations of protection against sunlight and UV radiation and against atmospheric oxygen assist each other synergistically. The compositions thus counteract hair damage and unwanted lightening of hair. Furthermore, the dye components in coloured products are protected.
Cognitive behavioral group therapy (CBGT) will be delivered by two Ph.D. clinical psychologists trained by Dr. Richard Heimberg to implement his CBGT for SAD (Heimberg \& Becker, 2002). Groups of six individuals will meet for 12 sessions of 2.5 hours each. The participants will also use selected portions of the client workbook developed by (Hope, Heimberg, \& Turk, 2010) to supplement relevant portions of the protocol. The treatment will be comprised of four major components: (1) psychoeducation and orientation to CBGT; (2) cognitive restructuring skills; (3) graduated exposure to feared social situations, within session and as homework; and (4) relapse prevention and termination. Further details of the treatment are available elsewhere (Heimberg \& Becker, 2002).
Federated learning (FL) has emerged as a significant method for developing machine learning models across multiple devices without centralized data collection. Candidemia, a critical but rare disease in ICUs, poses challenges in early detection and treatment. The goal of this study is to develop a privacy-preserving federated learning framework for predicting candidemia in ICU patients. This approach aims to enhance the accuracy of antifungal drug prescriptions and patient outcomes. This study involved the creation of four predictive FL models for candidemia using data from ICU patients across three hospitals in China. The models were designed to prioritize patient privacy while aggregating learnings across different sites. A unique ensemble feature selection strategy was implemented, combining the strengths of XGBoost's feature importance and statistical test p values. This strategy aimed to optimize the selection of relevant features for accurate predictions. The federated learning models demonstrated significant improvements over locally trained models, with a 9% increase in the area under the curve (AUC) and a 24% rise in true positive ratio (TPR). Notably, the FL models excelled in the combined TPR + TNR metric, which is critical for feature selection in candidemia prediction. The ensemble feature selection method proved more efficient than previous approaches, achieving comparable performance. The study successfully developed a set of federated learning models that significantly enhance the prediction of candidemia in ICU patients. By leveraging a novel feature selection method and maintaining patient privacy, the models provide a robust framework for improved clinical decision-making in the treatment of candidemia.
Dietary modifications can help to prevent and manage many chronic diseases. The Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diets emphasize consumption of fruits and vegetables while reducing intake of red meat. These diets are supported by well-established evidence for patients with cardiovascular disease and hypertension, respectively. Whole-food, plant-based diets have been shown to result in reduced body weight, lower A1c levels, and decreased insulin resistance in patients with diabetes. Patients with diabetes and hypertension should adhere to a heart-healthy diet, such as the DASH diet. For patients with diabetes and at risk of diabetes, key nutritional recommendations include emphasizing intake of nonstarchy vegetables, minimizing intake of added sugars and refined grains, and choosing whole foods instead of processed foods. The Dietary Guidelines for Americans, 2020-2025 recommend that adults limit sodium intake to less than 2,300 mg/day. Patients with chronic kidney or liver disease should follow sodium restriction and protein intake guidelines. Patients with irritable bowel syndrome should follow a low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet with fiber supplementation. For patients with gastrointestinal symptoms, fiber can effectively manage constipation and stool irregularity. Probiotic supplements or foods can be useful for digestive problems.
This study aims to analyze post-mortem human cardiac specimens, to verify and evaluate the existence or extent of oxidative stress in subjects whose cause of death has been traced to sepsis, through immunohistological oxidative/nitrosative stress markers. Indeed, in the present study, i-NOS, NOX2, and nitrotyrosine markers were higher expressed in the septic death group when compared to the control group, associated with also a significant increase in 8-OHdG, highlighting the pivotal role of oxidative stress in septic etiopathogenesis. In particular, 70% of cardiomyocyte nuclei from septic death specimens showed positivity for 8-OHdG. Furthermore, intense and massive NOX2-positive myocyte immunoreaction was noticed in the septic group, as nitrotyrosine immunostaining intense reaction was found in the cardiac cells. These results demonstrated a correlation between oxidative and nitrosative stress imbalance and the pathophysiology of cardiac dysfunction documented in cases of sepsis. Therefore, subsequent studies will focus on the expression of oxidative stress markers in other organs and tissues, as well as on the involvement of the intracellular pattern of apoptosis, to better clarify the complex pathogenesis of multi-organ failure, leading to support the rationale for including therapies targeting redox abnormalities in the management of septic patients.
A low cost, easy to use cleanser and/or treatment formulation (available in a powder, liquid, or solid form) includes encapsulated, non-toxic, timed-release dye. The dye remains encapsulated during cleansing and/or treating, such as during hand washing for the recommended 15-20 seconds. The encapsulant then releases the dye indicating that the hands have been thoroughly washed. Once the dye/lather mixture is completely removed by rinsing, the hand washer is assured that his or her hands have been thoroughly washed and rinsed completely. In those cases where an anti-bacterial agent is recommended, it should be used for the recommended 15-20 seconds, in order to be effective. The invention may be formulated for any type of timed cleaning and/or treatment, including hair washing, pet cleaning, hair coloring, and so forth. The cleansing formulation may be aqueous or organic based and may include encapsulated scents, lotions, medicants, therapeutic agents, and/or anti-microbials.
Embodiments of the present disclosure pertains to a genetically altered bacterial strain that lacks functional versions of at least three of the following proteins: FbpA; SapM; Zmpl; DosR; FadD26; SigH; nuoG; and Eis. In some embodiments, the bacterial strain lacks functional versions of at least the following proteins: FbpA; SapM; Zmpl; and DosR. In some embodiments, the bacterial strain lacks functional versions of at least the following proteins: FbpA; SapM; Zmpl; DosR; FadD26; and SigH. In some embodiments, the bacterial strain lacks functional versions of at least the following proteins: SapM; Zmpl; and nuoG. Further embodiments of the present disclosure pertain to methods of treating or preventing a bacterial infection in a subject by administering to the subject a bacterial strain of the present disclosure. In some embodiments, the bacterial infection is tuberculosis.
The present invention provides double-stranded RNA molecules that mediate RNA  interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA (dsRNA) molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering RNAs (siRNAs) using human Dicer.  The invention provides modified RNA molecules that are modified to include a dsRNA or siRNA wherein one or more of the pyrimidines in the RNA molecule are modified to include 2'-Fluorine. The invention also provides dsRNA or siRNA in which all pyrimidines are modified to include a 2'-Fluorine. The invention provides that the 2'-Fluorine dsRNA or siRNA molecule is further modified to include a two base deoxynucleotide "TT" sequence at the 3' end of the molecule.
BACKGROUND: Severe and/or symptomatic hypocalcemia due to hypoparathyroidism is the main contraindication for discharge in patients who have undergone thyroid surgery. Hypomagnesemia may contribute to the onset of hypoparathyroidism and is frequently observed after thyroid surgery in hypocalcemic patients. The impact of prophylactic and postoperative Magnesium supplementation on postoperative hypocalcemia and hypomagnesemia was prospectively evaluated by comparing patients undergoing prophylactic supplementation to a control group of patients who had only received magnesium after evidence of postoperative hypomagnesemia.
METHODS: One hundred and twenty patients who underwent a total thyroidectomy participated in the study. Seventy-three patients were included in the study group, 47 in the control group. Prior to surgery, patients in the study group were given magnesium orally for 5 days; postoperatively, calcium and magnesium was administered to all patients who displayed hypocalcemia and hypomagnesemia.
RESULTS: Postoperative biochemical hypocalcemia (serum calcium <8.5 mg/dL, regardless of its clinical severity) was found in 60 patients (50%) on D1 and in 58 patients (48.4%) on D2. Among hypocalcemic patients, hypomagnesemia was recorded in 29 at D1 (48%), and in 46 at D2 (79%). A significant positive correlation was found between magnesium, calcium, and parathyroid hormone in the first two postoperative days, while a significant inverse correlation occurred for these same parameters and length of hospital stay (P<0.001). One hundred and five patients (87.5%) were discharged as expected on the second postoperative day (65 in the study group, 40 in the control group, P=0.724), whereas 15 patients (12.5%) required prolonged hospitalization (eight in the study group, seven in the control group, P=0.721). The Study group only showed significantly higher magnesium levels on the first postoperative day (P=0.03).
CONCLUSIONS: Although magnesium and calcium levels showed the same trend after thyroidectomy, neither Magnesium prophylaxis nor Magnesium treatment influenced the clinical course of postoperative hypocalcemia.
INTRODUCTION: Nephrotic syndrome may persist despite end-stage kidney disease and result in dyslipidaemia, thrombosis and a significantly increased cardiovascular risk. Treatment of refractory nephrotic syndrome includes surgical bilateral nephrectomy, renal artery embolization and pharmacologic nephrectomy.
CASE PRESENTATION: We present a case of a haemodialysis patient with refractory nephrotic syndrome who underwent pharmacologic nephrectomy. The procedure decreased the patient's cardiovascular risk and enabled the patient to become a candidate for kidney transplantation.
CONCLUSION: In certain situations residual renal function may be harmful. In such instances, nephrectomy should be considered. Pharmacologic nephrectomy using nephrotoxic drugs is a non-invasive approach with least potential complications.
The invention provides a Leg1 protein, a Leg1 gene and application thereof to non-human animals and relates to the technical field of functions and application of the genes. By taking an mLeg1 gene knocked-out mouse as a research object, functions of an mLeg1 gene are very comprehensively researched by utilizing means of genetics, molecular biology, biochemistry and cell biology. A research result proves that an mLeg1 protein (SEQ ID NO. 2) and homologous proteins thereof (SEQ ID NO. 1 and SEQ ID NO. 5 to SEQ ID NO. 8), and coding genes thereof can be used as brand-new target points of fat synthesis related drugs and can be used in the fields of preparation of fat synthesis regulating related drugs including drugs for adjusting fat accumulation of vertebrates and the like; a brand-new concept is provided for developing and researching the drugs for adjusting fat synthesis accumulation in the vertebrates.